SARS-CoV-2 Reactive T Cells Associated with Protection from Covid-19
SARS-CoV-2 reactive T cells may be sufficient to give protection from covid-19, and serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.
Read MorePosted by Melanie Hamilton-Basich | Nov 24, 2020 | Covid 19 |
SARS-CoV-2 reactive T cells may be sufficient to give protection from covid-19, and serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.
Read MorePosted by Laurie Bonner | Nov 24, 2020 | Compliance, Covid 19 |
The two new templates offer recommendations on what to include in emergency use authorization requests for serology tests.
Read MorePosted by Laurie Bonner | Nov 24, 2020 | Covid 19, Information Technology |
Reports generated by BD Synapsys 3.84 Informatics Solution simplify mandatory public health reporting.
Read MorePosted by Laurie Bonner | Nov 24, 2020 | Company News, Covid 19 |
After its expected launch, T-Detect Covid will be the first clinical T-cell-based diagnostic test able to confirm past infections to SARS-CoV-2.
Read MorePosted by Laurie Bonner | Nov 24, 2020 | Company News, Covid 19, Swabs |
The HHS and DOD joint award is to expand production capacity of Cue Sample Wands, used exclusively with the covid-19 cartridge-based molecular testing system developed and manufactured by Cue Health.
Read More